Birabresib dihydrate

Mfr.No.	T69963
Molecular Formula	C25H26ClN5O4S
Signaling Pathways	Others
Description	Birabresib dihydrate was initially developed by Mitsubishi Tanabe Pharma Corporation, but then was licensed by OncoEthix, privately held biotechnology company. OTX015 is a selective bromodomains: BRD2, BRD3, and BRD4 inhibitor and inhibits their binding to AcH4. Bromodomains have an important role in the targeting of chromatin-modifying enzymes to specific sites, including methyltransferases, HATs and transcription factors and regulate diverse biological processes from cell proliferation and differentiation to energy homeostasis and neurological processes. OTX015 has potent antiproliferative activity accompanied by c-MYC down-regulation in several tumor types, and has demonstrated synergism with the mTOR inhibitor everolimus in different models. Oral administration of OTX-015 markedly inhibited tumor growth and reduced tumor volume. OTX015 is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors such as Triple Negative Breast ......
Smiles	O.O.Cc1sc-2c(c1C)C(=N(CH)(CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1
Cas Number	204587-26-8
Molecular Weight	528.02
Target	Others

Have you used this product?

SKU	Supplier No.	Size	Your price
BHB20437230	T69963	25 mg	$1520	Add to Cart
BHB20437230	T69963	50 mg	$1980	Add to Cart
BHB20437230	T69963	100 mg	$2500	Add to Cart